Active Biotech to Present at the UBS Global Life Sciences Conference


The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.
A replay will be available approximately three hours following the presentation and can be accessed via the company's web site.
To access the live and replay presentations please go to -
The presentation will take place on September 27, at 9:00 am US Eastern Time / 15:00 Central European Time.
About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects comprise the three orally administered compounds in clinical development, TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA as well as the I-3D project in pre-clinical co-development with Chelsea Therapeutics.
Active Biotech AB U.S. Investors
Cecilia Hofvander Kathy Price / Emmanuelle Ferrer
P.O. Box 724, SE-220 07 Lund, SwedenThe Global Consulting Group
Tel: +46 (0)46-19 20 00Tel: +1-(646) 284-9430 / +1-(646) 284-9421
Fax: +46 (0)46-19 20 50Email: /